Inland Peptides
Inland Peptides

Liraglutide

Research Snapshot Last reviewed October 2026
Yes

Approved by the FDA for human use

Yes

Studied in human clinical trials

Yes

Published human research

Yes

Published animal research

Primary research areas
  • Weight loss
  • type 2 diabetes
  • cardiovascular risk

Overview

Liraglutide is a peptide developed by Novo Nordisk. It is sold as Saxenda for weight management and Victoza for type 2 diabetes. Both are prescription medicines given by daily injection.

FDA-approved liraglutide medicines, including generic versions, are available by prescription and should be taken under a doctor’s care.

What is it being studied for?

Research on liraglutide covers weight loss, type 2 diabetes, and reducing the risk of heart attack and stroke in people with diabetes.

Liraglutide acts on the GLP-1 receptor, which helps regulate appetite, insulin release after a meal, and how fast the stomach empties.

What has research found?

In a 56-week study, adults with obesity and no diabetes who received a daily study dose of 3 milligrams lost about 8 percent of their body weight. Those given a placebo lost about 3 percent.

A separate study followed adults with type 2 diabetes and high cardiovascular risk for roughly four years. Heart attack, stroke, or cardiovascular death occurred less often with liraglutide than with a placebo.

Common side effects included nausea, vomiting, and diarrhea. The prescribing information carries a boxed warning about thyroid C-cell tumors found in rodents.

FDA status and development history

Liraglutide is approved for human use. The Food and Drug Administration cleared it in 2010 for type 2 diabetes under the name Victoza and in 2014 for weight management under the name Saxenda. Generic versions are now approved.